The Routing Problem: Why Drone Organ Transport Has Been Stuck Since 2019

UNOS and NASA signed a partnership agreement on April 21, 2026 at UNOS headquarters in Richmond, Virginia, and immediately launched Phase 1 of a study aimed at solving one of the most unglamorous problems in medical logistics: the first-mile and last-mile routing that connects organs to the patients who need them.

Phase 1 will fly instrumented UAVs carrying research or animal organs while sensors measure how temperature, vibration, and altitude affect viability. NASA Langley, through its CERTAIN testing program, provides a capability called beyond-visual-line-of-sight flight certification — the technical piece that lets drones operate without ground-based spotters tracking the route in real time. That capability, the agencies are betting, is what has blocked scaled deployment since 2019.

That year, a custom-built drone flew a human kidney 2.8 miles across Baltimore and a 44-year-old woman received a successful transplant. It was the first organ ever delivered by drone. The University of Maryland team called it unprecedented. The medical press ran it as a glimpse of the future, according to Maryland Today.

The future has not arrived. Seven years later, no one has repeated it at scale.

That gap between proof-of-concept and deployed system is what UNOS and NASA are now trying to close — and their bet on BVLOS certification as the bottleneck is the most concrete signal yet that the routing problem, not the drone technology, is what has kept this field stuck.

John Koelling, director of aeronautics research at NASA Langley Research Center, put the work in plain terms. "Doing something in my backyard that could change the world — how cool is that? That's almost as cool as stepping foot on the moon," he said in the UNOS press release. Mark Johnson, interim CEO of UNOS, framed it as infrastructure thinking rather than a single flight test. "NASA will also analyze potential flight routes, time savings, and ways drone technologies could be integrated into existing transplant logistics, focusing on a first-mile, last-mile route network," the release said.

The distinction matters. A drone that can carry a kidney across town under controlled conditions is a research result. A drone that can reliably pick up an organ at a rural hospital, navigate low-altitude urban airspace, and land at a transplant center without a human tracking its every move is a logistics system. That second thing has never been built, and the 2019 Maryland demonstration did not get there.

The routing problem is not primarily a drone problem. Drone technology has advanced considerably since 2019. The issue is the infrastructure surrounding the flight: who approves the route, who monitors weather and obstacles, who handles the handoff at each end, and how the system handles a failure mid-flight without the organ being lost or the aircraft becoming a hazard.

UNOS facilitated more than 46,000 transplants in 2023, setting records for kidney, liver, and lung procedures. The organization operates the undergirding logistics network that matches donor organs with recipients and coordinates the complex choreography of surgery scheduling, transport, and delivery. Getting a drone to work within that network means solving routing, timing, and certification problems that no single drone company has solved alone.

NASA's role is to provide the testing infrastructure that generates the data regulators need to approve broader operations. CERTAIN — City Environment Range Testing for Autonomous Integrated Navigation — is a program designed specifically for real-world BVLOS flight certification in complex environments. Using it to study organ transport is a signal that the agencies see the routing and certification problem as the actual bottleneck, not the drone hardware.

This is not the first time a major institution has tried to move drone organ transport past the demonstration stage. Several companies have piloted short-range medical drone deliveries in the years since 2019, primarily in Africa and Asia where the regulatory environment for drone flights is less restrictive than in the United States. The ScubaTx blog, which covers medical drone logistics, has documented how the FAA's regulatory framework in the U.S. created additional hurdles for commercial medical drone operations that comparable programs abroad did not face. A working group established under the FAA 2024 Reauthorization Act produced a set of recommendations in May 2025 on integrating medical drones into national airspace, though none have yet been implemented as binding rules.

What UNOS and NASA are doing is narrower than a commercial rollout. Phase 1 produces data. The data, if the program stays on track, gives the FAA a body of evidence to evaluate BVLOS operations for medical cargo. That evidence, if it exists and holds up, changes the calculus for any company that wants to build a commercial drone organ transport network.

The open question is whether seven years of stalling reflects a hard technical problem or a softer set of regulatory and economic constraints that NASA and UNOS together can finally unblock. The partnership announcement does not answer that question. It sidesteps it deliberately, framing the work as a study rather than a deployment plan. That caution is appropriate for a Phase 1, but it also means the most aggressive claims about drone organ transport remain speculative.

What is concrete: the routing problem exists, it has kept drone organ transport at demonstration scale for seven years, and two of the most credible institutions in American aviation and transplant medicine are now treating it as the problem worth solving. Whether they solve it, and whether the solution arrives before the next proof-of-concept makes headlines, is the story after this one.